Skip to main content

News Releases & Statements

News Releases & Statements

FDA Approves the First Interferon for Adults With Polycythemia Vera

Rye Brook, N.Y., November 16, 2021 – The U.S. Food and Drug Administration (FDA) last week announced approval of ropeginterferon alfa-2b-njft (ropeg, BESREMi®) for the treatment of polycythemia vera (PV). This is the first medication approved for PV that patients can take regardless of their treatment history, meaning it can be used to treat this rare form of cancer early, which may help reduce the risk of progression over time.

 

Read More

FDA Approves New Treatment Option for Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

Rye Brook, N.Y., November 11, 2021 – The U.S. Food and Drug Administration (FDA) recently granted accelerated approval to asciminib (Scemblix®) for patients with Philadelphia chromosome-positive chronic myeloid leukemia chronic phase (Ph+ CML-CP) who did not tolerate or had inadequate response to treatment with tyrosine kinase inhibitors (TKIs). FDA also approved asciminib to treat adult patients with Ph+ CML-CP with the T315I mutation.

 

Read More
LLS

LLS Statement on the Death of Former Secretary of State Colin Powell

Rye Brook, N.Y., October 18, 2021 LLS mourns the passing of Colin Powell. His death is a reminder of the seriousness of the pandemic and the ongoing need to protect the most vulnerable in our society.

Read More
The

The Able Channel Announces First Foundational Partner

(New York, NY - Sept. 28, 2021) — The Able Channel, the world’s first streaming digital health platform delivering inspiration, information, and innovation for families meeting the challenges of disability & lifelong health concerns, has announced The Leukemia & Lymphoma Society (LLS) as its first foundational partner. Read More

FDA Approves New Treatment Option for Common and Serious Complication of Life-saving Stem Cell Transplants

Rye Brook, N.Y., September 24, 2021 — The U.S. Read More

Leading Experts Provide Guidance on Maximizing COVID-19 Protection among Blood Cancer Patients

Rye Brook, N.Y., September 21, 2021 – A diverse group of cancer experts from leading academic institutions (UCLA, Emory University, NYU, Stanford University), the National Cancer Institute, and The Leukemia & Lymphoma Society (LLS) published recommendations for maximizing protection against COVID-19 among patients with blood cancer. The paper was published online in Blood Cancer Discovery, a journal of the American Association for Cancer Research.

Read More

New Drug Approval Expands Treatment Options for Patients with Marginal Zone Lymphoma

Rye Brook, N.Y., September 17, 2021 - The U.S. Read More

Media Requests

Please send all media-related inquiries and interview requests to mediarelations@lls.org.  An LLS representative will respond as soon as possible.